Shares of InVivo Therapeutics (OTC:NVIV) area up today despite wider 1st-quarter operating losses, as investors react to news that the medical device company will seek a listing on either the New York Stock Exchange or the NASDAQ exchange.
MassDevice Earnings Roundup
Accuray touts new order volume amid sinking sales, widening losses in Q3
Mako Surgical gains on Q1 results
Mako Surgical (NSDQ:MAKO) shares are up today after the medical device company reported lower 1st-quarter losses and affirmed its guidance for the rest of the year.
Diabetes: Wall Street cheers Insulet’s spike in sales, narrowed losses
Volcano puts up Q1 red ink, lowers forecast
Hologic slips on missed Q2 revenues, lowered outlook
Mela Sciences boosts its coffers in Q1
Mela Sciences (NSDQ:MELA) boosted its cash position in the 1st quarter, raising $21.5 million from a combination of sources.
The Irvington, N.Y.-based company raised $15.7 million in public offerings of company stock and an additional $6 million in debt financing during the start of its fiscal year.
The strange case of the diabetes market
Masimo gains on Q1 numbers, affirmed guidance
Masimo (NSDQ:MASI) shares are up following the Irvine, Calif.-based medical device company’s solid 1st-quarter results, gaining some 7% since last week’s earnings announcement.
Masimo, which makes patient monitoring equipment, posted profits of $16.4 million, or 28¢ per share, on sales of $135.9 million during the 3 months ended March 30, for bottom-line growth of 4.1% and a top-line gain of 14.0%.
Thoratec shares drop 10% on a harsh 1st quarter report
Allergan rebounds after Q1 numbers send shares down 13%
Allergan (NYSE:AGN) took a ride on the wild side this week as Wall Street pounded the medical aesthetics company after its 1st-quarter earnings release, initially sending share down more than 13%.
Some of the selloff appeared related to news that Irvine, Calif.-based Allergan is delaying the rollout of Darpin, its macular degeneration drug. Investors were also spooked by lowered guidance for 2013 and a bottom-line writedown over the sale of its Lap-Band business.